These findings support the use of urinary BCP as a biomarker of exposure to profenofos in humans and suggest polymorphisms in CYP 2 C 19 and CYP 2B6 as potential biomarkers of susceptibility.
These findings support the use of urinary BCP as a biomarker of exposure to profenofos in humans and suggest polymorphisms in CYP 2 C 19 and CYP 2B6 as potential biomarkers of susceptibility.